Trials / Completed
CompletedNCT06102915
Rocuronium vs Cis-atracurium: Do Rocuronium Still 'ROCKS' In Coronary Artery Bypass Grafting
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 289 (actual)
- Sponsor
- Institut Jantung Negara · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The current trend in most cardiac surgeries was to use rocuronium as it provides faster recovery in train-of-four ratio compared to other aminosteroid non-depolarising neuromuscular blocker. However, as most cardiac centres' standard of care does not perform any neuromuscular monitoring nor antagonism of neuromuscular blockade effect, residual neuromuscular blockade could potentially be the key to delayed extubation. As such, Cis-atracurium's organ-independent Hofmann elimination could be in favour.
Conditions
- Neuromuscular Blockade
- Postoperative Pulmonary Atelectasis
- Postoperative Pulmonary Complication
- Coronary Artery Disease
- Coronary Artery Bypass Grafting
- Hypothermic Cardiopulmonary Bypass
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rocuronium Bromide 10 MG/ML | Comparative |
| DRUG | Nimbex 10 MG in 5 ML Injection | Comparative |
Timeline
- Start date
- 2023-08-01
- Primary completion
- 2023-11-23
- Completion
- 2023-11-23
- First posted
- 2023-10-26
- Last updated
- 2023-11-28
Locations
1 site across 1 country: Malaysia
Source: ClinicalTrials.gov record NCT06102915. Inclusion in this directory is not an endorsement.